Synthesis, preclinical evaluation and pilot clinical study of a P2Y12 receptor targeting radiotracer 18FQTFT for imaging brain disorders by visualizing anti-inflammatory microglia.
10.1016/j.apsb.2025.01.009
- Author:
Bolin YAO
1
;
Yanyan KONG
2
;
Jianing LI
1
;
Fulin XU
3
;
Yan DENG
1
;
Yuncan CHEN
4
;
Yixiu CHEN
4
;
Jian CHEN
1
;
Minhua XU
5
;
Xiao ZHU
5
;
Liang CHEN
4
;
Fang XIE
2
;
Xin ZHANG
4
;
Cong WANG
1
;
Cong LI
1
Author Information
1. School of Pharmacy, MOE Key Laboratory of Smart Drug Delivery, MOE Innovative Center for New Drug Development of Immune Inflammatory Diseases, Zhongshan Hospital, Fudan University, Shanghai 201203, China.
2. PET Center, Department of Nuclear Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China.
3. Department of Neurosurgery, Minhang Hospital, Fudan University, Shanghai 201199, China.
4. Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China.
5. Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai 201203, China.
- Publication Type:Journal Article
- Keywords:
Aging;
Brain diseases;
Epilepsy;
Glioma;
Microglia;
Neuroinflammation;
P2Y12 receptor;
Positron emission tomography (PET)
- From:
Acta Pharmaceutica Sinica B
2025;15(2):1056-1069
- CountryChina
- Language:English
-
Abstract:
As the brain's resident immune cells, microglia perform crucial functions such as phagocytosis, neuronal network maintenance, and injury restoration by adopting various phenotypes. Dynamic imaging of these phenotypes is essential for accessing brain diseases and therapeutic responses. Although numerous probes are available for imaging pro-inflammatory microglia, no PET tracers have been developed specifically to visualize anti-inflammatory microglia. In this study, we present an 18F-labeled PET tracer (QTFT) that targets the P2Y12, a receptor highly expressed on anti-inflammatory microglia. [18F]QTFT exhibited high binding affinity to the P2Y12 (14.43 nmol/L) and superior blood-brain barrier permeability compared to other candidates. Micro-PET imaging in IL-4-induced neuroinflammation models showed higher [18F]QTFT uptake in lesions compared to the contralateral normal brain tissues. Importantly, this specific uptake could be blocked by QTFT or a P2Y12 antagonist. Furthermore, [18F]QTFT visualized brain lesions in mouse models of epilepsy, glioma, and aging by targeting the aberrantly expressed P2Y12 in anti-inflammatory microglia. In a pilot clinical study, [18F]QTFT successfully located epileptic foci, showing enhanced radioactive signals in a patient with epilepsy. Collectively, these studies suggest that [18F]QTFT could serve as a valuable diagnostic tool for imaging various brain disorders by targeting P2Y12 overexpressed in anti-inflammatory microglia.
